Supplementary Table 7. Comparison of baseline characteristics and outcomes between included and excluded patients

	Included (n=319)	Excluded (n=138)	*P**
Age (yr)	73.6±12.2	71.1±12.0	0.044
Male sex	171 (53.6)	83 (60.1)	0.196
Medical history†			
Hypertension	227 (72.1)	90 (65.7)	0.174
Diabetes	123 (39.0)	25 (18.2)	<0.001
Dyslipidemia	128 (40.6)	36 (26.3)	0.004
Coronary artery disease	53 (16.8)	18 (13.1)	0.322
Atrial fibrillation	168 (53.3)	70 (51.1)	0.661
Current smoking	38 (12.1)	29 (21.2)	0.012
Current alcohol consumption	69 (21.9)	37 (27.0)	0.239
Family history of ischemic stroke	48 (15.2)	17 (12.4)	0.431
mRS at one day prior to the ischemic stroke onset			0.018
0	244 (76.5)	119 (86.2)	
1	75 (23.5)	19 (13.8)	
Initial NIHSS score	13 (10–17)	14 (10–17)	0.741
ASPECTS	8 (6–9)	8 (6–9)	0.659
Occlusion site			
Intracranial ICA	82 (25.7)	39 (28.3)	0.570
MCA M1	190 (59.6)	84 (60.9)	0.793
M1-equivalent M2	78 (24.5)	27 (19.6)	0.254
TOAST classification			0.875
CE	194 (60.8)	85 (61.6)	
Non-CE	125 (39.2)	53 (38.4)	
Intravenous thrombolysis	149 (46.7)	82 (59.4)	0.013
eTICI‡			0.034
0	14 (4.5)	1 (0.7)	
1	7 (2.2)	5 (3.7)	
2a	25 (8.0)	4 (2.9)	
2b	129 (41.1)	49 (36.0)	
2c	70 (22.3)	38 (27.9)	
3	69 (22.0)	39 (28.7)	
Time from onset to ED arrival (min)	96 (49–208)	103 (53–250)	0.293
Time from arrival to thrombectomy (min)	108 (81–141)	91 (72–112)	<0.001
Time from arrival to intravenous alteplase (min)	42 (29–57)	33 (27–42)	0.007
HbA1c (%)	6.2±1.2	6.0±1.1	0.061
Admission glucose (mg/dL)	141.4±44.2	141.5±56.2	0.989
3-month mRS (shift analysis)	3 (1–4)	1 (0–3)	<0.001
Functional independence (mRS 0–2)	144 (45.1)	99 (71.7)	<0.001
Excellent outcome (mRS 0–1)	104 (32.6)	82 (59.4)	<0.001
Poor outcome (mRS 4–6)	137 (42.9)	29 (21.0)	<0.001
Symptomatic hemorrhagic transformation at day 5	7 (2.3)	1 (0.7)	0.445
Cerebral infarct volume (mL)			
Day 1	39 (12–115)	14 (6–64)	<0.001
Day 5	47 (17–154)	29 (10–94)	0.003
Week 12	13 (3–55)	8 (2–38)	0.114

Values are presented as mean±standard deviation, n (%), or median (interquartile range).
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; ICA, internal carotid artery; MCA, middle cerebral artery; TOAST, Trial of Org 10172 in Acute Stroke Treatment; CE, cardioembolism; eTICI, extended thrombolysis in cerebral infarction; ED, emergency department; HbA1c, hemoglobin A1c.
**P*-value by Cochran-Mantel-Haenszel shift test, chi-square test, Fisher's exact test, and Wilcoxon rank sum test; †Medical history was unavailable in 4 included and 1 excluded patient; percentages were calculated among patients with available data; ‡eTICI grade was unavailable in 5 included and 2 excluded patients.

https://doi.org/10.5853/jos.2026.03867